

## RECEIVED

AUG 1 5 2002

18810-80090

**TECH CENTER 1600/2900** 

## **AMENDMENT**

A Version with Markings To Show Changes Made is included after Applicant's Remarks.

## In the Specification:

At page 67, lines 5-9, please delete the paragraph and insert therefor the following paragraph:

Q'

--Control and hPTTG-transfected cells were tested for anchorage-independent growth in soft agar; 3 ml of soft agar (20% of 2X DMEM, 50% DMEM, 10% fetal bovine serum, and 20% of 2.5% agar, melted and mixed at 45°C) were added to 35-mm tissue dishes. 10,000 cells were mixed with 1 ml soft agar and added to each dish, and incubated for 2 weeks until colonies could be counted and photographed.--.

In the Claims:

Please cancel Claims 8, 24-41, 44, 45, 48, and 49, without prejudice, as being directed to a non-elected claim group. Further, please cancel Claims 11-13, and 16, without prejudice. Please amend Claims 1, 9, 14, 15, 46, and 47 as follows.



1.(Amended) A method of inhibiting neoplastic cellular proliferation and/or transformation of a mammalian breast or ovarian cell, comprising:

delivering to a mammalian breast or ovarian cell that overexpresses *PTTG*, a composition comprising a *PTTG* carboxy-terminal-related polynucleotide, said polynucleotide encoding a *PTTG-C* peptide selected from the group consisting of

(A) peptides having an amino acid sequence consisting of SEQ ID NO:9; and